Neogen Chemicals Q4 FY26: Revenue up 22%, ₹161cr raise

The quarter in focus: results and capital plan converge

Neogen Chemicals reported a strong finish to FY26, with fourth-quarter growth across revenue and operating profit even as the company stepped up spending for its battery materials strategy. Alongside the results, the company disclosed a promoter-led capital infusion through a preferential allotment, aimed at supporting expansion in lithium-ion battery materials. The update matters because Neogen’s battery chemicals plan is capital-intensive and closely tied to customer qualification timelines. Management has also outlined specific milestones for commercial manufacturing and customer approvals in FY27. Separately, the company continues to work through the operational and financial impact of reconstruction at Dahej after a fire incident, with insurance recoveries underway.

Q4 FY26 numbers: revenue growth with steady EBITDA margin

For Q4 FY26, Neogen reported consolidated revenue of ₹247 crore, a 22% year-on-year increase. Consolidated EBITDA for the quarter rose 21% year-on-year to ₹44 crore. EBITDA margin stood at 17.8%, holding steady despite input cost pressures cited by the company. The quarter’s performance indicates that volume and execution helped offset near-term cost headwinds. Neogen’s commentary also linked the quarter’s progress to continued investment in capacity build-out, especially for battery materials.

FY26 snapshot: EBITDA flat, PAT declines

On a full-year basis, consolidated revenue for FY26 was ₹862 crore, up 11% from the previous year. Full-year EBITDA increased 1% to ₹137 crore, reflecting a more modest operating profit expansion compared with revenue growth. Consolidated profit after tax (PAT) for FY26 fell 17% to ₹29 crore. The divergence between revenue and PAT points to the combined effect of cost pressures, financing costs, and expansion-related spend referenced elsewhere in the company’s updates.

Promoters commit ₹161 crore via preferential allotment

Neogen’s promoters injected ₹161 crore through a preferential allotment, signalling continued backing for the battery materials roadmap. The company also issued a corrigendum in its EGM notice clarifying how the preferential issue proceeds will be used. Shareholders are expected to vote on the proposal at an extraordinary general meeting scheduled for 29 March 2026. The preferential issue is priced at ₹1,610 per equity share, which is at a premium to the floor price of ₹1,375.82. Post-issue, the promoter group’s shareholding is expected to rise from about 51.23% to about 53.01%.

Use of proceeds: Neogen Ionics gets the largest allocation

The company’s disclosed allocation plan breaks the ₹161 crore into three buckets. ₹100 crore is planned as an investment into its wholly owned subsidiary, Neogen Ionics Limited, to expand battery chemicals production capacity. Another ₹21 crore is earmarked for working capital needs. The balance ₹40 crore is allocated for general corporate purposes. The company framed this clarification as a step to address investor questions ahead of the EGM and to improve transparency on capital deployment.

Battery materials expansion: Pakhajan and commercial timelines

Neogen is investing in capacity additions, including the Pakhajan greenfield site focused on lithium-ion battery materials. The company said it plans to commence commercial manufacturing of critical electrolyte components in the first half of FY27. In earlier quarterly updates, it also indicated expectations for customer approvals and bulk shipments of lithium salts by the first half of FY27. Neogen’s stated strategic direction builds on its experience in specialised chemicals such as electrolyte salts and solvents. The company has positioned these investments as aligned with India’s broader localisation push in advanced materials.

Integration moves: Buli acquisition and Morita JV

Neogen has acquired the Buli Chemicals India Private Limited facility, which it said strengthens downstream integration capabilities. In addition, Neogen Ionics formed a joint venture with Japan’s Morita Investment Limited to manufacture and sell solid LiPF6 salt globally. Under the structure disclosed, Neogen will hold 80% while Morita will invest $10 million for a 20% share. The company has linked the JV to proven Japanese technology and diversification of supply chains away from China. It has also outlined a manufacturing sequence, with commercial production of electrolyte expected in the first half of FY27, followed by electrolyte salt production in the second half.

Dahej reconstruction and insurance recoveries remain a key variable

Neogen has previously indicated that profitability was impacted by post-fire operating and insurance costs, along with higher finance costs tied to Dahej reconstruction and expansion spends in Neogen Ionics. For the nine months ended December 31, 2025, the company reported receipt of ₹83.48 crore from insurance claims. It also disclosed that the net claim receivable reduced to ₹251.12 crore. The replacement plant construction has been described as progressing, with commissioning scheduled for Q1 FY27.

Market check: stock move and dividend proposal

Neogen Chemicals shares (NSE: NEOGEN) closed at ₹1,295.00 on 11 February at 3:30 pm IST, down ₹19.60 or 1.49% for the day. The stock opened at ₹1,313.90, hit an intraday high of ₹1,357.50, and touched a low of ₹1,289.60. Over the past 52 weeks, the stock has traded between a high of ₹2,059.45 and a low of ₹966.70. The company also recommended a final dividend of ₹1 per equity share for FY26, subject to shareholder approval. Separately, disclosures in the same set of updates referenced a dividend yield of around 0.077% and a quarterly dividend amount of ₹0.249 per share.

Key numbers and milestones at a glance

What investors are tracking into FY27

A near-term focus is the sequence of regulatory approvals for the preferential issue and the outcome of the 29 March 2026 EGM. Operationally, timelines around commissioning and commercial manufacturing in the first half of FY27 are central, especially for electrolyte components and customer qualification. Investors are also likely to watch progress on Dahej replacement plant commissioning in Q1 FY27 and the pace of insurance recoveries. Neogen has provided standalone revenue guidance of ₹875–950 crore for FY27, which sets a measurable benchmark against execution.

Conclusion

Neogen Chemicals ended FY26 with strong Q4 growth and stable operating margin, while promoters backed a ₹161 crore fundraise to support the battery materials push. The next set of milestones includes shareholder approval at the 29 March 2026 EGM, regulatory clearances, and progress toward commercial manufacturing in the first half of FY27.